Course of cannabis use and clinical outcome in patients with non-affective psychosis: a 3-year follow-up study
F J van der Meer, Eva Velthorst, Genetic Risk And Outcome Of Psychosis (group) Investigators
Psychological Medicine February 5, 2015 DOI: 10.1017/s0033291714003092 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational cohort Peer reviewed |
|---|---|
| Sample size | 678 |
| Population | Patients with non-affective psychotic disorders in the Netherlands and Belgium |
| Duration | 3-year follow-up |
| Measures | Positive and Negative Syndrome Scale (PANSS), Global Assessment of Functioning (GAF), psychotic relapse |
| Topics | Cannabis |
| Citations | 49 |
| Key findings | Persistent cannabis users had more positive and general symptoms, worse global functioning, and more psychotic relapses than non-users and discontinued users. Patients who started using cannabis after study onset had worse baseline functioning and increased general symptoms at 3-year follow-up. Timing of cannabis discontinuation was not associated with clinical outcome. |
Abstract
Background: Prospective studies on the relationship between course of cannabis use and clinical outcome in patients with non-affective psychotic disorders are inconclusive. The current study examined whether (1) persistent, recently started, discontinued and non-cannabis-using patients with a psychotic disorder differed with regard to illness outcome at 3-year follow-up, and (2) whether timing of cannabis discontinuation was associated with course of clinical outcome.
Method: This 3-year follow-up study was part of a multi-center study in the Netherlands and Belgium (Genetic Risk and Outcome of Psychosis; GROUP). We used mixed-model analyses to investigate the association between pattern of cannabis use and symptoms, global functioning and psychotic relapse.
Results: In our sample of 678 patients, we found persistent users to have more positive and general symptoms, worse global functioning and more psychotic relapses compared with non-users and discontinued users [Positive and Negative Syndrome Scale (PANSS) positive, p < 0.001; PANSS general, p < 0.001; Global Assessment of Functioning (GAF) symptoms, p = 0.017; GAF disability, p < 0.001; relapses, p = 0.038]. Patients who started using cannabis after study onset were characterized by worse functioning at baseline and showed an increase in general symptoms (including depression and anxiety) at the 3-year follow-up (p = 0.005). Timing of cannabis discontinuation was not associated with clinical outcome.
Conclusions: These findings suggest that cannabis use in patients with a psychotic disorder has a long-lasting negative effect on illness outcome, particularly when persistent. Treatment should focus on discouraging cannabis use.
Comparable studies
Other observational and cohort studies on cannabis, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| High-potency cannabis and the risk of psychosis People with first episode of psychosis and healthy controls from the local population | 2009 | Case-control study | n = 454 |
| Ayahuasca-Assisted Therapy for Addiction: Results from a Preliminary Observational Study in Canada Rural aboriginal population | 2013 | Observational study | |
| Impaired cognitive performance in drug free users of recreational ecstasy (MDMA) Otherwise healthy young people | 2000 | Observational | |
| Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study Individuals from the general population in Germany aged 14-24 at baseline | 2011 | Observational cohort | n = 1,923 |
| Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases Patients treated for cannabis-induced psychotic symptoms in Denmark between 1994 and... | 2005 | Observational cohort | n = 535 |
Citations in the library
Cited by 12
- Cognitive mechanisms in cannabis-related paranoia; Initial testing and model proposal Psychosis May 13, 2020
- Randomized Laboratory Study of Single-Dose Cannabis, Dronabinol, and Placebo in Patients With Schizophrenia and Cannabis Use Disorder Schizophrenia Bulletin June 20, 2024
- Distinguishing between cannabis-induced psychotic disorder and psychotic disorder with concurrent cannabis use: a diagnostic challenge Romanian Journal of Psychiatry & Psychotherapy June 30, 2020
- Cannabis Use and Clinical Outcomes in First Episode Psychosis: Results From a 2‐Year Follow‐Up Study Early Intervention in Psychiatry May 1, 2026
- Effects of persistent cannabis use on depression, psychosis, and suicidality following cannabis‐induced psychosis: A longitudinal study American Journal on Addictions September 1, 2025
and 7 more in the library
Cites 9
- Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study BMJ March 1, 2011
- Effects of cannabis use on outcomes of psychotic disorders: systematic review The British Journal of Psychiatry October 31, 2008
- Does Change in Cannabis Use in Established Psychosis Affect Clinical Outcome? Schizophrenia Bulletin October 29, 2011
- Cannabis and First-Episode Psychosis: Different Long-term Outcomes Depending on Continued or Discontinued Use Schizophrenia Bulletin November 13, 2009
- The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study. Psychological Medicine July 1, 2007
and 4 more in the library